-
Company Profile
![]()
Pharmacyclics LLC – Company Profile
Pharmacyclics LLC (Pharmacyclics), a subsidiary of AbbVie Inc, is a biopharmaceutical company which focuses on the development and commercialization of small-molecule medicines for the treatment of cancer and immune-mediated diseases. The company’s marketed product includes Imbruvica is an once-daily, first-in-class bruton's tyrosine kinase (BTK) inhibitor developed for the treatment of patients with chronic lymphocytic leukemia, mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma and chronic graft-versus-host disease. Its products candidate in clinical development includes Imbruvica BTK inhibitor intended for the...
Add to Basket -
Sector Analysis
OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2024
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. NHLs are further categorized into indolent or aggressive prognostic subtypes, which further influence the outcomes and treatment decisions. Patients diagnosed with indolent NHLs (follicular lymphoma [FL] or marginal zone lymphoma [MZL]) can achieve a median survival of 10 to 20 years, and relative...
-
Sector Analysis
B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2027
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of proliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. B-cell lymphomas comprise approximately 85% of all NHL cases diagnosed in the US, and are a diverse group of blood cancers that arise in the B-cells. This report focuses on the four NHL subtypes that represent the greatest commercial opportunities for drug developers...
-
Sector Analysis
Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027
Chronic lymphocytic leukemia (CLL) is a form of cancer that originates from lymphocytes in the bone marrow and later invades the blood and/or lymphoid tissues. CLL treatment has been transformed since the novel oral targeted agents Imbruvica (ibrutinib), Zydelig (idelalisib), and Venclexta (venetoclax) were introduced to the market from 2014 onwards and challenged the prior dominance of chemoimmunotherapy regimens. During the forecast period, the global CLL market will welcome five new drugs—Calquence (acalabrutinib), zanubrutinib, umbralisib, ublituximab, and Revlimid (lenalidomide). The...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.